- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Julie Reed Talks About How Savings Can Differ Between Patients, Health Plans
Julie M. Reed, the executive director of the Biosimilars Forum, discusses how biosimilar savings can differ between stakeholders and the importance of competition for creating those savings.
Julie M. Reed, the executive director of the Biosimilars Forum, discussed how biosimilar savings can differ between stakeholders and the importance of competition for creating those savings.
Transcript
How do the potential savings related to increased biosimilar utilization differ for health plans and patients?
That's a great question. I think it differs only in who the stakeholder is. The cost savings are there for everyone. Now, what really differs is the responsibility of the health plans. They can and should include all biosimilars on their formularies, and they should cover all biosimilars, and that gives patients and doctors access to all the biosimilars.
That's really key because what we know and our economic studies show is that the more biosimilars competing at the same time with the reference product, you're seeing the prices go down faster, you're seeing greater cost savings. If it's only 1 biosimilar vs all the biosimilars and having equal access and coverage, you're not seeing the robust competition that you could be having. That, in turn, [leads to] the price goes down, the co-pays go down, the prices for patients and everything else.
So, that's a key piece as far as the payers and their formularies, and Medicare, and the governments. They have a responsibility to really promote and increase the uptake to these lower-cost products.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Eye on Pharma: EU Aflibercept Approvals; Biosimilars Canada Campaign; Celltrion Data
November 19th 2024The European Commission grants marketing authorization to 2 aflibercept biosimilars; Biosimilars Canada launches new campaign to provide sustainable solutions to employers; Celltrion shares positive data for 2 biosimilars.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Breaking Down Biosimilar Barriers: Interchangeability
November 14th 2024Part 3 of this series for Global Biosimilars Week, penned by Dracey Poore, director of biosimilars at Cardinal Health, explores the critical topic of interchangeability, examining its role in shaping biosimilar adoption and the broader implications for accessibility.
